Microbio awarded AMGC support for sovereign manufacture of core IP for biothreat tests

Australian biotech company Microbio has been awarded an Australian Government Advanced Manufacturing Growth Centre (AMGC) co-investment of $407,000 to enable the company to establish sovereign manufacturing capabilities in Australia for a test to identify potential biological threats. The company will manufacture specific oligonucleotides, a unique component used in its product suite, which includes InfectID-BSI, InfectID-COVID… Continue reading Microbio awarded AMGC support for sovereign manufacture of core IP for biothreat tests

Introducing Microbio’s new consultant – Dr Raffaella Giardino

Microbio’s new consultant Dr Raffaella Giardino has extensive experience in highly regulated markets such as in vitro diagnostics (IVD), medical devices, and pharmaceuticals, as well as new market development, operations, finance, sales, and marketing. In her role as a remote consultant, Raffaella will support Microbio as it moves into Europe with the Blood Stream Infection… Continue reading Introducing Microbio’s new consultant – Dr Raffaella Giardino

Microbio prepares for first deliveries in India

Microbio is pleased to announce it has appointed a distributor in India for its range of COVID-19 tests. The appointment of Indian firm, BioGTech, follows the approval of Microbio’s COVID-19 tests by the Indian Council of Medical Research (ICMR), and validation testing by Rajiv Gandhi Centre for Biotechnology (RGCB). The first deliveries to India are… Continue reading Microbio prepares for first deliveries in India

Microbio moves toward sovereign manufacturing of diagnostic tests

This is a Caption

Microbio has moved into new laboratories at Brisbane’s Translational Research Institute (TRI) with the aim of eventually setting up domestic manufacturing capability. More information can be found in the media release:211019_Microbio_moves_toward_sovereign_manufacturing_of_diagnostic_tests